RxDoctor Payments Data

David Riley, MD

Neurology · Beachwood, OHNPI 1568481976

Payments from drug & device makers

$86,325in general payments, 2019–2025

Across 239 payments — averaging $361.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$68K
  • Ipsen Biopharmaceuticals, Inc$10K
  • Merz North America, Inc.$5K
  • Merz Pharmaceuticals, LLC$2K
  • Amneal Pharmaceuticals LLC$198
  • Sunovion Pharmaceuticals Inc.$157
  • plus $587 from 11 others
$23,071in research payments, 2019–2025

Across 4 payments — averaging $5767.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$23K

What the payments were for

  • Consulting fees$6,6258%
  • Speaking & faculty fees$69,49781%
  • Travel & lodging$5,9587%
  • Food & beverage$4,2465%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,325 in reported general payments places this provider in the 80th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$318,491
Medicare patients
136
Services billed
40,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate11$55,898
NeuproRotigotine13$12,601
Carbidopa-LevodopaCarbidopa/Levodopa165$6,453
AmantadineAmantadine Hcl42$1,802
Clonazepam78$1,766
Trihexyphenidyl Hcl35$1,219
Rasagiline Mesylate15$1,182
Baclofen42$865
Pramipexole DihydrochloridePramipexole Di-Hcl27$793
Mirtazapine23$716
Propranolol Hcl17$676
Primidone20$675
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$424
Gabapentin29$328
Benztropine Mesylate17$304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$42$55,89811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 702 neurology providers in Ohio.

Other neurology in Beachwood

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →